Maurie Markman, MD

The Essential But Often Complex Role of Numbers and Measurements in Oncology

November 20th 2025

Maurie Markman, MD, discusses the evolving role of measurements in cancer care.

Concerns Escalate About the Fundamental Integrity of Scientific Peer-Reviewed Literature

October 31st 2025

Older Cancer Clinical Trials May Continue to Offer Relevant Lessons Learned

October 5th 2025

Maurie Markman, MD, details the lessons learned following results from older clinical trials within the oncology space.

Recognizing the Rapidly Changing World of Surgical Oncology

September 29th 2025

Maurie Markman, MD, discusses the evolution of surgical oncology, from radical resections to multidisciplinary, minimally invasive, and neoadjuvant approaches.

Is It Time to Revisit How We Measure and Report the Toxicities of Antineoplastic Pharmaceutical Agents?

August 20th 2025

Maurie Markman, MD, discusses the need to reevaluate how adverse effects are measured and reported with antineoplastic therapies in oncology.

Dr Markman on Future Research Directions in Gynecologic Oncology

July 21st 2025

Maurie Markman, MD, discusses future research considerations in gynecologic oncology.

A Closer Look at Issues With the Expanding Role of Precision Medicine in Cancer Management

July 11th 2025

Maurie Markman, MD, raises concerns about public health priorities and resource allocation in light of the expanding role of precision medicine in cancer.

Dr Markman the Significance of PROs in Patients With Locally Advanced Cervical Cancer

June 19th 2025

Maurie Markman, MD, discussed the significance of patient-reported outcomes from the phase 3 OUTBACK trial in locally advanced cervical cancer.

Clinical Judgment in the Provision of Optimal Care vs Selection Bias in a Survival Analysis

May 29th 2025

Maurie Markman, MD, explores the key role of clinical judgment in treatment decision-making and its impact on patient outcomes in cancer research.

On the Unreality of Cancer Care Finances in the US: An Example of the Emperor's New Clothes Syndrome?

May 14th 2025

Maurie Markman, MD, discusses the complexities of cancer care financing in the US, highlighting the need for innovative solutions amidst rising costs.

"Halfway Technology": Is It Time to Seriously Discuss Transitioning From the Current Focus of Cancer Research?

April 14th 2025

Maurie Markman, MD, discusses the potential to shift the focus of cancer research towards the "real high technology of medicine", such as cancer vaccines.

Ethical Considerations in the Conduct of Clinical Cancer Research Always a Timely Topic

March 28th 2025

The evolution of biomedical research continues to pose quite thorny ethical dilemmas.

Prognostic vs Predictive Factors in Oncology Carry Differing Intent but May Have Complementary Clinical Utility

March 3rd 2025

Maurie Markman, MD, discusses the differences between prognostic vs predictive factors and their clinical utility in oncology practice.

Unique Questions Associated With the Increasing Prominence of Precision/Genomic Medicine in Routine Cancer Care

January 23rd 2025

Maurie Markman, MD, delves into questions regarding precision medicine and genetic testing in cancer.

The Ongoing Debate: Progression-Free vs Overall Survival as the Primary Study Outcome in Therapeutic Cancer Trials

December 10th 2024

Is it time to end the rhetoric that denies the benefit of antineoplastic pharmaceutical agents due to the absence of an OS improvement in a clinical trial?

Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual Patients

November 20th 2024

Serious questions must be asked about the current state of interventional trials in the oncology sphere and how to improve their future value.

A Call to Action: Determining Optimal Dose, Schedule, and Appropriate Modifications for Antineoplastic Pharmaceutical Agents

November 4th 2024

The oncology community must reconsider its approach to defining optimal dosing and scheduling of antineoplastic agents.

The Escalating Need for Robust Decision Support in Oncology: Ovarian Cancer as an Example

October 24th 2024

The speed at which new drugs, combinations, and novel approaches are being introduced into routine practice presents a challenge for treating oncologists

Molecularly Targeted Therapeutics Are Precisely Aimed

October 10th 2024

Maurie Markman, MD, details how the precision-medicine paradigm is a highly rational platform for antineoplastic drug development.

The Scientific Validity of Peer-Reviewed Publications: A Concerning Situation With Implications for Oncology

October 3rd 2024

Maurie Markman, MD, discusses concerns regarding the scientific validity of peer-reviewed publications in oncology and their ramifications for the field.